NOTICIAS DIARIAS

Blood-plasma Infusions for Alzheimer’s Patients are Safe and may be Effective

Immuno Haematology & Blood Transfusion

Blood plasma infusion, Alzheimer's disease could be safe, feasible and improve their functional ability and capacity to perform daily tasks, according to a study led by the Stanford University School of Medicine Medicine

Tony Wyss-Coray, a professor of neurology from Stanford proposes a hypothesis that factors in the blood of young mice could revive the brain tissue of old mice and improve their cognitive functions. In order to test the hypothesis, the Stanford researchers developed an early-phase clinical trial called as PLASMA trial – short for Plasma for Alzheimer's Symptom Amelioration.

It was not surprising to find That Blood- plasma transfusion was safe, as it has – been in use for a long Widespread time for other Indications. But, the researchers surprised to find signs that the recipients had improved functional ability , which is the ability to engage in daily basic activities such as medication, paying bills or preparing meals, noted the study leader Sharon Sha.

The current trial involved two stages; In the first stage, nine people with mild-to-moderate Alzheimer's were received four-week infusions of either blood plasma taken from people aged 18-30 or placebo (saline solution). But the recipients were unaware of their infusions they have received. The regimens were swapped after a six-week "washout" period.

The respondents were completed with the tests and questionnaires before and after four-week infusion periods, which was designed to determine cognition, mood and functional ability among the participants.

The second stage involved nine participants who received the plasma from young donors, with both the participants and the caregivers being aware of this. These individuals were given the same tests and questionnaires to complete as the first group.

Following a four-week treatment period, the test outcomes were analyzed. Some of the functional ability tests showed a significant improvement in those participants from the first stage of the trial. However, there were no significant changes in the participants' mood or cognitive ability .

The current trial was not directed to determine the efficacy, so the researchers were astonished to find signs that the participants had improved functional ability. Further studies involving larger cohort would be required, as the present trial carried on a limited number of participants, Sharon Sha concluded.